Triple Mutant Bovine Herpes Virus-1 Vaccine
- 詳細技術說明
- This triple mutant Bovine Herpes Virus-1 (BHV-1) vaccine issuperior to current treatment methods as the mutant virus will not shedfollowing reactivation, will be DIVA competent, and will induce bettersecondary immunity responses.
- *Abstract
-
Bovine Herpes Virus Type 1 (BHV-1) is the cause ofinfectious bovine rhinotracheitis (IBR) in cattle, a severe respiratory tractinfection that can lead to complications such as abortion in pregnant cows anda substantial reduction in milk and meat production. BHV-1 is also acontributing factor in Bovine Respiratory Disease Complex (BRDC), otherwiseknown as shipping fever. IBR causesconsiderable losses for the cattle industry worldwide, and BRDC is estimated tocost the U.S. cattle industry at least $1 billion annually.
This novel genetically engineered vaccine for immunizationof cattle against BHV-1 lacks the critical amino acid residues of a viralenvelope protein important for suppressing the initial immune responsefollowing virus infection. In addition, this virus lacks the ability toreactivate from latency. Based on a vaccine efficacy study, this virus inducesa significantly better protective immune response in calves against BHV-1compared with vaccines for the wild type virus in the field and the BHV-1marker vaccine. Compared to the currently available vaccines, cattle vaccinatedwith the engineered vaccine virus will be better protected against the BHV-1infection.
- *IP Issue Date
- Nov 4, 2014
- *IP Type
- Utility
- *Licensing
- Robert J. Brown Assistant Director Tel: 225-615-8916 Email: rjbrown@lsu.edu
- 國家
- United States
- 申請號碼
- 8,877,211
- 國家/地區
- 美國
